Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Protagenic Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AS PUBLISHED IN BEHAVIOURAL PHARMACOLOGY, TWO DAYS OF PT00114 TREATMENT REDUCED CORTICOSTERONE LEVELS AND ATTENUATED ANXIETY-LIKE BEHAVIOR IN CHRONICALLY STRESSED RATS; A KNOWN CRF RECEPTOR ANTAGONIST DID NOT SHOW ACTIVITY IN THE SAME MODEL. NEW YORK, NY / ACCESS NEWSWIRE / JUNE 30, 2026 / PROTAGENIC THERAPEUTICS, INC. (OTCQB:PTIX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON NOVEL NEUROPEPTIDE THERAPIES FOR STRESS-RELATED DISORDERS, TODAY ANNOUNCED THE PUBLICATION OF NEW PRECLINICAL DATA FOR ITS LEAD CANDIDATE, PT00114, IN THE PEER-REVIEWED JOURNAL BEHAVIOURAL PHARMACOLOGY.

PROTAGENIC THERAPEUTICS' LEAD CANDIDATE PT00114 ATTENUATED CHRONIC STRESS RESPONSES IN A WELL-ESTABLISHED RODENT MODEL

NEW YORK, NY / ACCESS NEWSWIRE / MAY 19, 2026 / PROTAGENIC THERAPEUTICS, INC. (OTCQB:PTIX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPIES FOR STRESS-RELATED NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED TWO STRATEGIC ENGAGEMENTS TO SUPPORT THE ADVANCEMENT OF ITS LEAD CANDIDATE, PT00114. THE COMPANY HAS ENGAGED FLOYD REGULATORY STRATEGIC CONSULTING, LED BY REGULATORY AFFAIRS VETERAN DR. ERIC FLOYD, PH.D.

PROTAGENIC THERAPEUTICS ENGAGES FLOYD REGULATORY STRATEGIC CONSULTING AS REGULATORY AFFAIRS ADVISOR AND DANFORTH HEALTH AS STRATEGIC OPERATIONS PARTNER

NEW YORK, NY / ACCESS NEWSWIRE / APRIL 23, 2026 / PROTAGENIC THERAPEUTICS, INC. (OTCQB:PTIX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING FIRST-IN-CLASS NEUROPEPTIDE THERAPIES FOR STRESS-RELATED NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF BILL NICHOLS JR. AS PRESIDENT. THIS STRATEGIC LEADERSHIP ADDITION, COMBINED WITH A THOUGHTFUL OPTIMIZATION OF THE COMPANY'S MANAGEMENT STRUCTURE, SHARPENS FOCUS AND RESOURCES ON ADVANCING ITS LEAD CANDIDATE, PT00114 - POSITIONING PROTAGENIC FOR ACCELERATED CLINICAL PROGRESS AND LONG-TERM VALUE CREATION FOR PATIENTS AND SHAREHOLDERS ALIKE.

PROTAGENIC THERAPEUTICS APPOINTS INDUSTRY VETERAN BILL NICHOLS JR. AS PRESIDENT TO ACCELERATE ADVANCEMENT OF FIRST-IN-CLASS TCAP PATHWAY THERAPY PT00114

RETURNED AND CANCELLED MERGER SHARES, REMOVAL OF MORE THAN $6.3 MILLION OF LIABILITIES AND OVER $1 MILLION OF ANNUALIZED COST SAVINGS POSITION PROTAGENIC AS A LEANER COMPANY CENTERED ON PT00114 NEW YORK CITY, NY / ACCESS NEWSWIRE / MARCH 17, 2026 / PROTAGENIC THERAPEUTICS, INC. (OTCQB:PTIX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS TREATMENTS FOR STRESS-RELATED NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE CLOSING OF A SETTLEMENT AND SEPARATION RELATED TO ITS PRIOR PHYTANIX BIO ACQUISITION. THE TRANSACTION SIMPLIFIES PROTAGENIC'S CAPITAL STRUCTURE, MATERIALLY REDUCING LIABILITIES AND SHARPENS THE COMPANY'S OPERATING FOCUS ON PT00114.

PROTAGENIC THERAPEUTICS COMPLETES PHYTANIX SEPARATION, STRENGTHENS BALANCE SHEET AND REPOSITIONS THE COMPANY AROUND PT00114

MOVE STRENGTHENS MARKET VISIBILITY, SUPPORTS LIQUIDITY AND REAL-TIME QUOTE ACCESS AS PT00114 ADVANCES TOWARD PHASE 2 IN 2026 NEW YORK CITY, NY / ACCESS NEWSWIRE / MARCH 10, 2026 / PROTAGENIC THERAPEUTICS, INC. (OTCQB:PTIX) ("PROTAGENIC" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS TREATMENTS FOR STRESS-RELATED DISORDERS, INCLUDING TREATMENT-RESISTANT DEPRESSION AND ANXIETY, TODAY ANNOUNCED THAT ITS COMMON STOCK HAS BEEN UPGRADED FROM OTC PINK TO THE OTCQB AND HAS COMMENCED TRADING ON OTCQB UNDER THE SYMBOL "PTIX." THE OTCQB IS A RECOGNIZED PUBLIC MARKET FOR DEVELOPING COMPANIES THAT MEET DEFINED REPORTING, MANAGEMENT CERTIFICATION AND BID PRICE STANDARDS.

PROTAGENIC THERAPEUTICS UPGRADES FROM OTC PINK TO OTCQB VENTURE MARKET

FINDINGS SUPPORT ADVANCEMENT INTO PHASE 2 TO EXPLORE A FIRST-IN-CLASS PATHWAY AIMED AT STRESS-RELATED NEUROPSYCHIATRIC CONDITIONS NEW YORK CITY, NEW YORK / ACCESS NEWSWIRE / DECEMBER 9, 2025 / PROTAGENIC THERAPEUTICS INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING THERAPEUTICS THAT TARGET THE BIOLOGY OF CHRONIC STRESS AND ITS DOWNSTREAM PSYCHIATRIC AND NEUROLOGIC EFFECTS, TODAY REPORTED POSITIVE TOPLINE SAFETY RESULTS FROM ITS PHASE 1 MULTIPLE DOSE (MD) STUDY OF PT00114. PT00114 IS A SYNTHETIC ANALOGUE OF A NATURALLY OCCURRING BRAIN PEPTIDE THOUGHT TO BE INVOLVED IN RESTORING HOMEOSTASIS FOLLOWING PROLONGED EXPOSURE TO STRESS.

RESULTS FROM PHASE 1 MULTIPLE-DOSE STUDY OF PT00114

NEW YORK, NY / ACCESS NEWSWIRE / NOVEMBER 27, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) (THE "COMPANY") TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTIFICATION LETTER FROM THE NASDAQ LISTING QUALIFICATIONS STAFF (THE "STAFF") INDICATING THAT THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULES 5550(B)(1) (MINIMUM STOCKHOLDERS' EQUITY) AND 5250(C)(1) (TIMELY FILING OF PERIODIC REPORTS). THE STAFF DETERMINED THAT, BASED ON THE STOCKHOLDERS' EQUITY REPORTED IN THE COMPANY'S TRANSITION REPORT ON FORM 10-QT FOR THE PERIOD ENDED JUNE 30, 2025, THE COMPANY NO LONGER SATISFIES THE MINIMUM $2.5 MILLION STOCKHOLDERS' EQUITY REQUIREMENT UNDER LISTING RULE 5550(B)(1).

PROTAGENIC THERAPEUTICS ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE NOTICE

NEW YORK CITY, NY / ACCESS NEWSWIRE / NOVEMBER 13, 2025 / PROTAGENIC THERAPEUTICS INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR STRESS-RELATED NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISORDERS, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF ENROLLMENT AND DOSING IN ITS MULTIPLE ASCENDING DOSE (MAD) PHASE 1 STUDY EVALUATING ITS LEAD COMPOUND, KNOWN AS PT00114. THE STUDY, CONDUCTED IN HEALTHY VOLUNTEERS, WAS DESIGNED TO ASSESS THE SAFETY AND TOLERABILITY PROFILE OF PT00114 FOLLOWING MULTIPLE DOSES OVER TIME.

PROTAGENIC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN PHASE 1 MAD STUDY

DELAY ATTRIBUTABLE TO MERGER-RELATED FINANCIAL CONSOLIDATION NEW YORK, NY / ACCESS NEWSWIRE / AUGUST 22, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL NEURO-ACTIVE PEPTIDE THERAPIES, TODAY ANNOUNCED THAT IT EXPECTS TO FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2025 IN THE NEAR FUTURE, FOLLOWING A DELAY ATTRIBUTABLE TO THE COMPLETION OF MERGER-RELATED CONSOLIDATION OF FINANCIAL STATEMENTS, INCLUDING PURCHASE ACCOUNTING ADJUSTMENTS, PRO FORMA FINANCIAL INFORMATION, AND RELATED DISCLOSURES. WHILE THE COMPANY ANTICIPATES THIS DELAY TO BE BRIEF, THERE CAN BE NO ASSURANCE AS TO THE DEFINITIVE TIMING OF THE FILING.

PROTAGENIC THERAPEUTICS PROVIDES UPDATE ON FORM 10-Q FILING TIMELINE AND NASDAQ COMPLIANCE

DOSING COMPLETION EXPECTED BY END OF AUGUST; PHASE 2 TRIAL EXPECTED TO BEGIN IN 1Q 2026 NEW YORK, NY / ACCESS NEWSWIRE / AUGUST 21, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL NEURO-ACTIVE PEPTIDE THERAPIES, TODAY ANNOUNCED COMPLETION OF FIRST DOSE INJECTION FOR ALL STUDY SUBJECTS IN THE MULTIPLE-DOSE PORTION OF ITS ONGOING PHASE I CLINICAL TRIAL OF PT00114. THE COMPANY EXPECTS TO COMPLETE DOSING BY THE END OF AUGUST, WITH TOPLINE SAFETY DATA ANTICIPATED BY THE END OF SEPTEMBER, SUPPORTING ADVANCEMENT INTO PHASE 2 EFFICACY STUDIES PLANNED FOR THE FIRST QUARTER OF 2026.

Protagenic Therapeutics, Inc.

PTIX

Price

Financial Reports

No items found.

Press Releases

Protagenic Therapeutics, Inc.

PTIX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PTIX